Financial burden and financial toxicity in patients with colorectal, gastro-oesophageal, and pancreatobiliary cancers: a UK study

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Presenters

Nicola Flaum

Citation

Annals of Oncology (2018) 29 (suppl_8): viii562-viii575. 10.1093/annonc/mdy297

Authors

N. Flaum1, G. Papaxoinis1, K. Hockenhull1, J. Barriuso2, W. Mansoor1

Author affiliations

  • 1 Medical Oncology, The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
  • 2 Division Of Cancer Sciences, University of Manchester / The Christie NHS Foundation Trust, M20 4BX - Manchester/GB
More

Resources

Background

How cancer affects a patient (pt) in the UK financially and how this changes throughout treatment is unknown. We aimed to assess financial burden (FB) at baseline and financial toxicity (FT) throughout treatment of pts with upper GI (UGI), pancreatobiliary (PB) and colorectal (CR) cancers.

Methods

Pts with UGI, CR and PB cancer enrolled in 5 clinical trials (REAL-3, RAINFALL, ESPAC-4, QoL BIL and CAPITAL) at the Christie, Manchester, were identified. FB at baseline and FT throughout treatment were defined according to answers to the EORTC QLQ-C30 questionnaire (EQ) Q28 to which pts score financial difficulty relating to disease or treatment from 1 (not at all) to 4 (very much).

Results

141 pts were included, 58 (41.1%) received adjuvant and 83 (58%) palliative treatment. 96 (68.1%) were men; median age was 62 yrs (range 39-84). 15 (10.6%) pts had CR, 85 (60.3%) PB and 41 (29.1%) UGI cancer. 87 (61.7%) had no FB (scored 1 on EQ), 35 (24.8%) scored 2, 12 (8.5%) scored 3 and 7 (5%) scored 4. 97 (68.8%) answered ≥2 EQs. Median EQ follow up was 6.3 months (range 0.5-63.1). 63.5% experienced no FT, 19.8% worse FT and 16.7% improving FT. The median index of multiple deprivation (IMD) (the measure of relative deprivation of English regions) was 16,083 (range 3-32,041). Multiple regression analysis showed that younger age, lower IMD and tumor type were independent predictors of FB. Significant covariates included IMD below vs. above median (OR 2.64, 95%CI 1.13-6.15, p = 0.024) and age below vs. above median (OR 7.83, 95%CI 3.23-18.94, P < 0.001). Of these, no factor predicted FT. Pts who experienced FT were significantly younger compared to those who did not (median age 55 vs. 69, p < 0.001) and had significantly lower IMD (median 9,483.5 vs. 19,277, p = 0.002). IMD in our series did not show significant interaction with age (p = 0.270). Palliative treatment and lower IMD were independent predictors of worse overall survival.

Conclusions

We report the first study of FB and FT in pts with UGI, PB and CR cancers living in UK, identifying independent baseline parameters predicting FB and the prognostic role of IMD. Younger pts and those of lower IMD are at significantly higher risk and should be offered additional support.

Clinical trial identification

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Editorial Acknowledgement

NA

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

Working arrangements after cancer diagnosis: who, what, when and how?

Presenter: Caroline Alleaume

Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Resources:

Abstract

VOYAGER: An open-label, randomised, Phase 3 study of avapritinib vs regorafenib in patients (pts) with locally advanced (adv) metastatic or unresectable gastrointestinal stromal tumour (GIST)

Presenter: Sebastian Bauer

Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Resources:

Abstract

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings